RenovoRx (RNXT) EBIT (2024 - 2025)

RenovoRx (RNXT) has disclosed EBIT for 2 consecutive years, with -$3.5 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 33.81% to -$3.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$12.5 million through Dec 2025, down 14.04% year-over-year, with the annual reading at -$12.5 million for FY2025, 14.04% down from the prior year.
  • EBIT hit -$3.5 million in Q4 2025 for RenovoRx, down from -$3.2 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$2.5 million in Q1 2024 to a low of -$3.5 million in Q4 2025.